BIOLASE - BIOL Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1-year price objectives for BIOLASE's stock. Their BIOL share price forecasts range from $5.00 to $14.00. On average, they anticipate the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 872.5% from the stock's current price.
View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts.

BIOLASE's stock was trading at $9.75 at the beginning of the year. Since then, BIOL shares have decreased by 90.0% and is now trading at $0.9769.
View the best growth stocks for 2022 here.

BIOLASE saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 137,500 shares, an increase of 8.4% from the October 31st total of 126,900 shares. Based on an average daily trading volume, of 77,600 shares, the days-to-cover ratio is presently 1.8 days. Currently, 2.0% of the company's stock are short sold.
View BIOLASE's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our BIOL earnings forecast.

BIOLASE, Inc. (NASDAQ:BIOL) posted its earnings results on Wednesday, November, 10th. The medical technology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.25. The medical technology company earned $9.53 million during the quarter. BIOLASE had a negative net margin of 51.38% and a negative trailing twelve-month return on equity of 118.42%. During the same period in the previous year, the business earned ($5.25) EPS.

BIOLASE's stock reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

BIOLASE updated its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $13.00M-, compared to the consensus revenue estimate of $12.55 million.

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

BIOLASE's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (10.20%), Perkins Capital Management Inc. (1.93%), Essex Investment Management Co. LLC (1.47%) and Citadel Advisors LLC (0.25%). Insiders that own company stock include Jack W Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg.
View institutional ownership trends.

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOL stock can currently be purchased for approximately $0.98.

BIOLASE (NASDAQ:BIOL) has a market capitalization of $6.98 million and generates $39.19 million in revenue each year. The medical technology company earns $-16,160,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis.

The company employs 158 workers across the globe.

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.